Study Details
Design, interventions, and primary outcomes
About This Study
This phase II trial studies how well a vaccine, STEMVAC, works in combination with standard endocrine-based therapy (ET) with a CDK4/6 targeted drug therapy, or with the chemotherapy drug capecitabine, in treating patients with hormone receptor (HR)-positive, HER2-negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic). STEMVAC is designed to target proteins that cancer cells use when they become more aggressive and start to spread, and it is believed to work by boosting the immune system to recognize and destroy the invader tumor cells that are causing the disease. Standard ET is treatment that adds, blocks, or removes hormones in order to slow or stop the growth of cancer. Standard CDK4/6 inhibitors, including abemaciclib, may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Capecitabine is in a class of medications called antimetabolites. It is taken up by tumor cells and breaks down into fluorouracil, a substance that kills tumor cells. Giving STEMVAC in combination with standard ET or chemotherapy may be an effective treatment for metastatic HR positive, HER2 negative breast cancer.
Design
Interventions / Regimen
- Biological: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine — Given ID
- Drug: Capecitabine — Given SOC capecitabine
- Procedure: Computed Tomography — Undergo CT or ultrasound-guided biopsies
- Drug: Cyclin-Dependent Kinase 4 Inhibitor — Given SOC CDK4/6i
- Drug: Cyclin-Dependent Kinase 6 Inhibitor — Given SOC CDK4/6i
- Drug: F-18 16 Alpha-Fluoroestradiol — Undergo FES PET
- Drug: Hormone Therapy — Given SOC ET
- Procedure: Positron Emission Tomography — Undergo PET or FES PET
Primary Outcomes
- Incidence of adverse events (AEs) (Up to 3 years after completion of study treatment)
- Incidence of immunogenicity (Pre-vaccine up to after 2 booster doses of STEMVAC vaccine (Up to 40 weeks))
Phase: PHASE2
Status: Recruiting
Start Date: 2025-11-17
Completion: 2028-12-31
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
- Natasha Hunter, MD (PRINCIPAL_INVESTIGATOR) - Fred Hutch/University of Washington Cancer Consortium
- Biological: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine — Given ID
- Drug: Capecitabine — Given SOC capecitabine
- Procedure: Computed Tomography — Undergo CT or ultrasound-guided biopsies
- Drug: Cyclin-Dependent Kinase 4 Inhibitor — Given SOC CDK4/6i
- Drug: Cyclin-Dependent Kinase 6 Inhibitor — Given SOC CDK4/6i